BTK

Actions
  1. Inhibitor (13)


13 Item(s)

per page

Set Descending Direction
Catalog No. Product Name Product Information
A15824

ACP-196 (Acalabrutinib)

ACP-196 is an orally available inhibitor of Bruton‘s tyrosine kinase (BTK) with potential antineoplastic activity. It inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway.
A13202

AVL-292

AVL-292 is a highly selective, covalent Btk inhibitor.
A15008

AVL-292 benzenesulfonate

AVL-292 benzenesulfonate is a covalent, highly selective, orally active small molecule inhibitor of Btk with IC50 value of 0.5 nM, >1400-fold selectivity over the other kinases assayed.
A16260

Btk inhibitor 1

Btk inhibitor 1 is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.
A11348

CGI1746

CGI1746 is a small-molecule Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.
A13233

CNX-774

CNX-774 is a potent Btk inhibitor (IC50 < 1 nM)
A12706

GDC-0834

GDC-0834 is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis.
A16261

LFM-A13

LFM-A13 is a potent and selective inhibitor of Btk with IC50 of 17.2 uM; also inhibits PLK3 with IC50 of 7.2 uM.
A15976

Olmutinib (HM71224)

Olmutinib is a potent small molecule inhibitor of Bruton's tyrosine kinase (BTK).
A15558

ONO-4059

ONO-4059 is a highly potent and selective oral BTK inhibitor
A16262

PCI 29732

PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.
A11020

PCI-32765

PCI-32765 is an orally bioavailable small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.
A16263

QL47

QL47 is a potent, selective and irreversible BTK kinase inhibitor with IC50 of 7 nM.

13 Item(s)

per page

Set Descending Direction